MJuLLINGER Bernkhard (DE),МЮЛЛИНГЕР Бернхард (DE),ShOJKh Gerkhard (DE),ШОЙХ Герхард (DE),KhOFMANN Tomas (US),ХОФМАНН Томас (US),KRONEBERG Filipp (DE),КРОНЕБЕРГ Филипп (DE),MJULLINGER BERNKHARD,МЮЛЛИНГЕР Бернхард,SHOJKH GERKHARD,ШОЙХ Герхард,KHOFMANN TOMAS,ХОФМАНН Томас,KRONEBERG FILIPP,КРОНЕБЕРГ Филипп
申请号：
RU2011135824/15
公开号：
RU0002519344C2
申请日:
2010.02.03
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
FIELD: medicine.SUBSTANCE: invention refers to methods of treating a patient suffering from severe and uncontrolled asthma which involve pulmonary administration of a glucocorticoid in the form of a vapour-phase nebulised aerosol in a combination with oral administration of a glucocorticoid. According to one of the declared methods, the nebulised aerosol is administered by inhalation at no more than 20 l/min rate in the total inhalation volume of at least 0.4 l of the vapour phase； t administration of the nebulised aerosol is preceded by administering no more than 150 ml of aerosol-free air. The glucocorticoid is administered in a daily dose of no more than 40 mg of prednisolone and an equivalent dose of another glucocorticoid. The other method of treating the patient involves pulmonary administration of the glucocorticoid in an amount of 400 to 4,000 mcg with using a nebuliser which is used to administer the glucocorticoid aerosol into the lower portion of the lungs at excessive pressure of 40 mbar or less that leads to deposition of more than 200 mcg of the glucocorticoid in the lower portion of the lungs. What is also declared is a method of treating the patient which involves pulmonary administration of the glucocorticoid in the amount of 400 to 4,000 mcg with the aerosol administered by inhalation consisting of three pre-specified periods wherein after the third period, the patient is advised to stop inhaling and exhale； the presented treatment leads to deposition of more than 200 microgram of the glucocorticoid in the lower portion of the lungs.EFFECT: invention provides improved deposition of the inhaled glucocorticoid in the lower portion of the lungs, min 30% less consumption of oral glucocorticoids and fewer oropharyngeal side effects.16 cl, 1 exИзобретение относится к способам лечения пациента, страдающего тяжелой и неконтролируемой астмой, которые включают введение пациенту глюкокортикоида в ингаляционной форме в виде распыленного аэрозоля в газовой фа
